TerminatedNCT00947791
Treatment Study of Depression in bipolarity
Medication studyAges 21–70United States
Understand this study
Who could participate?
Listed age limits: 21 years to 70 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateJuly 2009
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 1
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 21 Years to 70 Years
- Official registry ID
- NCT00947791
- Official title
Show the full official title
Intravenous Ketamine in Treatment-Resistant Bipolar Depression
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Icahn School of Medicine at Mount Sinai, a university.
Does this study involve medication?
Yes. The study involves medication, including ketamine and midazolam.
Who can participate?
Listed age limits: 21 years to 70 years.
Is this study still recruiting?
The registry lists this study as terminated.
